Jazz Pharmaceuticals Plc, headquartered in Dublin, focuses on developing treatments for narcolepsy, oncology, pain, and psychiatry, employing 2,800 staff since its IPO in 2012. Key products include Xywav, Xyrem, and Defitelio.
Patricia Carr sold 1,140 shares of JAZZ on 10 March at $137.81 per share, worth a total of $157K. They now own 7,012 JAZZ shares, or a 14% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
